Immunotherapy in Brain, Head and Neck Cancer
No contributors found.
Release Date: 2024-06-12
Besides immunotherapy, several other pathways are targeted in Head and Neck (HNC) for future treatment. HRAS, NTRK, MSI, NOTCH, and PIK3A are targetable pathways for HNC. Tipifarnib showed promising results in patients with HNC having HRAS mutation in phase 2 studies. Xevinapant, a potent oral inhibitor of the apoptosis proteins antagonist, is another novel molecule [...]
